News

Evosep receives $40m investment from Novo Holdings

Published

on

International life science investor Novo Holdings has today announced a $40m investment in bioscience company, Evosep.

Proceeds from the investment will be used to advance clinical applications of proteomics enabled by Evosep’s standardised liquid chromatography platform.

The new funds will also enable Evosep to further expand its presence globally, especially in the rapidly growing US market.

Christian Ravnsborg, CEO, Evosep, said:

“We are delighted to have Novo Holdings A/S as a new shareholder in Evosep.

“Novo Holdings is a well-known and highly regarded long-term investor with significant expertise in working with innovative life sciences businesses to unlock their potential.

“The combined experience and investment will enable us to accelerate our already strong growth and further expand our platform towards bedside care proteomics, both independently and through our many vendor relationships.”

Evosep aims to improve quality of life and patient care using liquid chromatography–mass spectrometry (LC-MS) for drug discovery.

It also seeks to innovate how protein-based clinical diagnostics are performed across panels with multiple protein biomarkers.

Stephen Van Helden, Principal, Novo Holdings, said:

“Evosep’s technology can profoundly impact the diagnosis and treatment of diseases.

“Its platform addresses some of the most common technical pain points that have historically held back the widespread application of proteomics.”

Following the investment, Van Helden join Evosep’s Board of Directors.

He added:

“We are impressed with the Evosep team, the incredible culture of the company and the platform they’ve commercialised in such a short time.

“Novo Holdings is excited to be part of Evosep’s continued growth as the company increases its momentum and global presence.”

Denmark’s Export and Investment Fund is among Evosep’s existing investors and has been investing in the company since 2016.

Tonni Bülow-Nielsen, Partner at Denmark’s Export and Investment Fund, said:

“Evosep has already proven its potential to become among the global leaders in proteomics, and I have great faith in the team.

“The success of the company is a testimony to Denmark’s unique position within health tech, and at Denmark’s Export and Investment Fund we are pleased to continue the journey with Evosep in partnership with Novo Holdings.

“We are confident that Evosep, with their advanced technology, will create significant positive change in the healthcare sector.”

Click to comment

Trending stories

Exit mobile version